ArticleInvestigative ophthalmology & visual science2025
The Transcription Factor Islet-1 Regulates Diabetes-Induced Inner Blood-Retinal Barrier Disruption.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Bumetanide‑blocked SLC12A2 exerts a protective effect in experimental diabetic retinopathy.International journal of molecular medicine · 2026Article
- CD36 Regulates PANoptosis in Diabetic Retinopathy via the NOTCH/MAML Pathway.Journal of diabetes research · 2026Article
- Endothelial mitochondrial-derived vesicles (EMDVs) with retinal targeted homing properties dynamically modulate the eIF2α-ATF4-CHOP signaling pathway and efficiently restore mitochondrial homeostasis in diabetic retina.Journal of nanobiotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The transcription factor Islet-1 (Insulin gene enhancer protein Isl-1) has been implicated in diabetic retinal neovascularization, but its role in inner blood-retinal barrier (iBRB) dysfunction in diabetic retinopathy remains unclear. This study aimed to elucidate the mechanisms by which Islet-1 drives iBRB disruption under diabetic conditions by integrating analyses of clinical samples from patients with diabetic retinopathy, in vivo studies in diabetic mouse models, and in vitro experiments using hyperglycemia-exposed human retinal microvascular endothelial cells. Methods: The expression profile of Islet-1 in diabetic patients and experimental diabetic models were investigated by immunofluorescence staining, Western blot (WB) and quantitative real-time polymerase chain reaction (qRT-PCR). Through the modulation of Islet-1 expression, we evaluated its impact on iBRB integrity under diabetic conditions and explored the molecular pathways involved in iBRB disruption. Results: Our findings demonstrated that elevated Islet-1 expression correlates with the progression of diabetic retinopathy and the breakdown of the iBRB. Mechanistically, Islet-1 upregulation led to increased vascular endothelial growth factor A (VEGFA) expression and decreased levels of key tight junction proteins Occludin and Zonula occludens-1 (ZO-1) in retinal vascular endothelial cells. Conclusions: Our results establish Islet-1 as a critical regulator of iBRB disruption in diabetic retinopathy and suggest that targeting Islet-1 overexpression may represent a novel therapeutic approach to mitigate iBRB dysfunction and its associated retinal pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.